reductions in placental (15%; pb0.002) and fetal (54%; p b0.002) weights in RAGE -/-mice compared to SHS-exposed controls. In the fetus, their lung showed increased apoptosis, decreased collagen IV expression (2.5-fold; pb0.05), increased MMP-9 (3-fold; p b0.05), increased TNF-(3.8-fold; p b0.05) and increased IL-1 (7-fold; pb0.05) expression. All of these were profoundly reduced in the RAGE -/-mice compared to SHS-exposed controls. We concluded that SHS-induced IUGR is directly influenced by RAGE and that SHS directly affects fetal lung development in a RAGE dependent manner. These studies provide insight into tobacco-mediated IUGR development and clarify avenues that may be helpful in the alleviation of fetal lung SHS-induced complications. Myeloproliferative neoplasms (MPNs) are clonal hematopoietic disorders that cause excessive proliferation of specific myeloid lineages. The majority of MPN patients have a point mutation in the JAK2 gene (JAK2V617F) encoding a dominant-active kinase that constitutively triggers JAK/STAT signaling. In Drosophila, the JAK/STAT pathway is conserved but simplified, with a single JAK Hopscotch (Hop) and a single STAT (Stat92E). The hopTum-l allele encodes a dominant-active kinase that hyper-activates Stat92E. Like MPN patients, hopTum-l mutants have dramatically increased myeloid cells (called plasmatocytes and lamellocytes), which aggregate to form lethal melanotic tumors.
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Myeloproliferative neoplasms (MPNs) are clonal hematopoietic disorders that cause excessive proliferation of specific myeloid lineages. The majority of MPN patients have a point mutation in the JAK2 gene (JAK2V617F) encoding a dominant-active kinase that constitutively triggers JAK/STAT signaling. In Drosophila, the JAK/STAT pathway is conserved but simplified, with a single JAK Hopscotch (Hop) and a single STAT (Stat92E). The hopTum-l allele encodes a dominant-active kinase that hyper-activates Stat92E. Like MPN patients, hopTum-l mutants have dramatically increased myeloid cells (called plasmatocytes and lamellocytes), which aggregate to form lethal melanotic tumors.
We performed a sensitized deficiency screen to find dominant modifiers of hopTum-l tumors. A deficiency that uncovers Enhancer of Polycomb (E(Pc)) significantly enhanced the melanotic tumor burden in hopTum-l animals, as did heterozygosity for E(Pc) hypomorphic alleles. Moreover, hematopoietic depletion of E(Pc) in an otherwise wild-type background caused precocious differentiation of lamellocytes and melanotic tumors. E(Pc) is a component of the Tip60 Histone Acetyl Transferase complex. In support of the model that E(Pc) functions through the Tip60 complex in blood cells, depletion of Tip60 or other complex components resulted in precocious lamellocyte differentiation and small melanotic tumors.
We next addressed whether the E(Pc) tumor phenotype was dependent on JAK/STAT activity. Indeed, depletion of Stat92E inhibited tumor formation caused by E(Pc) knock down, indicating an epistatic interaction between E(Pc)/Tip60 and Stat92E. Furthermore, we showed that E(Pc) mutant cells have increased expression of Stat92E target genes. These data strongly suggest that E(Pc) represses tumor formation by attenuating JAK/STAT activity, possibly by either direct acetylation of Stat92E or by transcriptional induction of suppressors of Stat92E. Biochemical approaches and whole genome sequencing will be used to distinguish between these possibilities. In sum, we have identified a new regulator of hematopoiesis in Drosophila that may have conserved functions in higher organisms. Here we provide fundamental insights into early human development by single-cell RNA-sequencing of human and mouse preimplantation embryos. We elucidate conserved transcriptional programs along with those that are human-specific. Importantly, we validate our RNA-sequencing findings at the protein level, which further reveals differences in human and mouse embryo gene expression. For example, we identify several genes exclusively expressed in the human pluripotent epiblast including the transcription factor KLF17. Key components of the TGF-β signaling pathway including NODAL, GDF3, TGFBR1/ALK5, LEFTY1, SMAD2, SMAD4 and TDGF1 are also enriched in the human epiblast. Intriguingly, inhibition of TGF-β signaling abrogates NANOG expression in human epiblast cells, consistent with a requirement for this pathway in pluripotency. Although key trophectoderm factors Id2, Elf5, and Eomes are exclusively localized to this lineage in the mouse, the human orthologues are either absent or expressed in alternative lineages. Importantly, we also identify genes with conserved expression dynamics including Foxa2/FOXA2, which we show is restricted to the primitive endoderm in both human and mouse embryos. Comparisons of the human epiblast to existing embryonic stem cells (hESCs) reveals conservation of pluripotency but also additional pathways more enriched in hESCs. Our analysis highlights significant differences in human preimplantation development compared to mouse and provides a molecular blueprint to understand human embryogenesis and its relationship to stem cells. Here, we report sixteen patients from twelve families presenting with a new syndrome characterized by an epileptic encephalopathy and a mild to profound global developmental delay.
To unravel the genetic etiology of this new syndrome, we performed a trio whole-exome sequencing in one consanguineous family. Assuming an autosomal recessive inheritance, we discovered a rare homozygous missense mutation (c.244CNG; p.Ala82Thr) in UGDH that segregates with the disease. The patients from the eleven other families also carry biallelic mutations (homozygous or compound heterozygous) in UGDH, including three nonsense mutations, suggesting that this disease arises from loss-of-function mutations in UGDH.
UGDH (OMIM603370) encodes an oxidoreductase that converts UDP-glucose to UDP-glucuronate, used in glycosaminoglycans biosynthesis. UGDH knockout leads to severe, but distinct developmental abnormalities in several animal models; however no germline mutation has been reported in human yet.
Using patients' fibroblasts harboring the p.Ala82Thr mutation, we show that it does not alter UGDH mRNA expression, but that its protein level is decreased relative to control cells. Biochemically, UGDHA82T was unable to form hexamers like UGDHWT and was more prone to proteolysis. Consistently, NADH enzymatic reduction by UGDHA82T was significantly decreased relative to UGDHWT.
To confirm the A82T pathogenicity in vivo, we performed rescue experiments using jekyll zebrafish embryos that carry a mutation in the ugdh gene. Interestingly, ugdhWT mRNA injection was able to fully rescue the jekyll phenotype, while ugdhA82T mRNA injection failed to do so.
In the brain, hyaluronan is the major glycosaminoglycan of the extracellular matrix and its deficiency in mice leads to altered neuronal activity and seizures. We thus hypothesize that a deficiency in UGDH activity might give rise to a deficit in hyaluronan production in the developing brain, which could explain the phenotypes of this hitherto undescribed syndrome. Diabetes mellitus is a group of chronic metabolic disorders characterized by inappropriate hyperglycemia. It has been estimated that this disease will affect 7.8% of the world adult population by 2030. Diabetic cardiomyopathy is the leading cause contributing to the increased morbidity and mortality in diabetic patients. Endothelial dysfunction has been reported in diabetic animal models and patients to induce cardiac remodeling and dysfunction. However, the mechanisms by which hyperglycemia induces endothelial dysfunction are not fully understood and currently no specific therapy is available. We and others have demonstrated the cardioprotective role of follistatin-like 1 (FSTL1) under various pathological stresses, including excessive nitric oxide, myocardial infarction, ischemic reperfusion, and pressure overload. However, whether FSTL1 mediates cytoprotection against hyperglycemia-induced endothelial dysfunction remains to be further elucidated. Human umbilical vein endothelial cells (HUVECs) were cultured in endothelial growth medium-2 (EGM-2) (normal glucose, NG). In the high glucose (HG)-treated group, cells were incubated with EBM-2 containing an extra 25 mM of D-glucose. We demonstrated that FSTL1 treatment significantly attenuates hyperglycemia-induced tube formation and migration disability of endothelial cells. Our study provides novel insights into the cardioprotective role of FSTL1 on hyperglycemiainduced endothelial dysfunction. Liver fibrosis is the scarring process that represents the liver's intrinsic response to injury. This gradual scarring of the liver puts people at risk to develop liver cirrhosis and liver cancer. We have identified several patients from two families with chronic liver fibrosis that is caused by homozygous loss of function mutations in a Protein Disulfide Isomerase (PDI). This family of enzymes resides in the endoplasmic reticulum (ER) and is important for the proper folding of proteins via disulfide bridging. Mutation from one family results in a protein null while the other results in loss of PDI enzymatic activity. Characterization of patient fibroblasts show elevated expression of ER stress genes. Loss of PDI activity is known to cause protein misfolding. Accumulation of misfolded proteins can activate the ER stress mechanism which aims to restore ER homeostasis or initiate cell death. This PDI is expressed in both hepatocytes and hepatic stellate cells in the human liver. Knockdown of PDI in immortalized hepatocytes increases the expression of ER stress genes. Previous studies have implicated ER stress in contributing to fibrosis. Together, our data suggests that increased ER stress may be a mechanism that contributes to the initiation and progression of liver fibrosis. Robinow Syndrome is characterized by 'fetal facies' and is caused by mutations in the WNT5A ligand, the adaptor protein DVL or the receptor ROR2. Patients typically have a wider midface which suggests that embryonic facial narrowing was disrupted. In order to model Robinow syndrome we inserted mutant genes into the chicken embryo face. We knocked in C-terminal nonsense mutations into human Dishevelled 1 that cause autosomal dominant Robinow Syndrome (DRS2, OMIM 616331). Either wild-type or mutant DVL1 constructs were cloned into RCAS retroviruses and injected into the stage 15 frontonasal mass. External phenotypes: by stage 29-30 the egg tooth formed in all embryos indicating that epithelialmesenchymal interactions were unaffected. The frontonasal mass was broader than normal and shorter in sagittal plane (8/12). At stage 38, there was significant upper beak shortening for 1519ΔT, 1529ΔG (6/7 and 13/14). In contrast, the wtDVL1 embryos had mild deviations (9/25) or were normal (15/25). Molecular results: There were no changes in proliferation 48h post-infection. However, there were many changes in gene expression at 48h that were specific to mutant DLV1. AXIN2, LEF1, BMP2, SOX9 and ROR2, WNT5A, Prickle, ALX1 and ALX4 were downregulated in DVL1
1519ΔT infected embryos.
In contrast, ROR2, SOX9 and VANGL2 were increased in wtDVL1. These gene differences reduce the likelihood that phenotypes are only due
